Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
复制标题
DOI：
10.1021/acs.jcim.1c01451
复制
发表时间：
2022-01-06
影响因子：
5.6
通讯作者：
Wei, Guo-Wei
中科院分区：
文献类型：
--
作者：
Chen, Jiahui;Wang, Rui;Wei, Guo-Wei
最新的严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)变异株Omicron(B.1.1.529)因其传染性和疫苗逃逸突变而在世界各地引发恐慌反应。SARS-CoV-2变种的基本传染性和抗体抵抗力是由其尖峰蛋白受体结合域(S)上的突变决定的。然而，对奥美康进行完整的实验评估可能需要数周甚至数月的时间。在这里，我们对奥美康的传染性、疫苗突破性和抗体耐药性进行了全面的定量分析。人工智能(AI)模型已经用数万个实验数据进行了训练，并通过对SARS-CoV-2的实验结果进行了广泛验证，该模型显示，Omicron的传染性可能是原始病毒的10倍以上，或者是Delta变体的2.8倍左右。根据185个抗体-RBD复合体的三维(3D)结构，我们揭示了奥米克隆可能有88%的可能性逃脱当前的疫苗。美国食品和药物管理局(FDA)批准的礼来公司的单抗(MAbbs)可能会严重受损。奥美康也可能降低阿斯利康、Regeneron单抗鸡尾酒、Celltrion和洛克菲勒大学单抗的疗效。然而，它对葛兰素史克Sotrovimab的影响似乎是温和的。我们的工作需要新的战略来开发下一代抗突变的SARS-CoV-2疫苗和抗体。
The latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron (B.1.1.529) has ushered panic responses around the world due to its contagious and vaccine escape mutations. The essential infectivity and antibody resistance of the SARS-CoV-2 variant are determined by its mutations on the spike (S) protein receptor-binding domain (RBD). However, a complete experimental evaluation of Omicron might take weeks or even months. Here, we present a comprehensive quantitative analysis of Omicron's infectivity, vaccine breakthrough, and antibody resistance. An artificial intelligence (AI) model, which has been trained with tens of thousands of experimental data and extensively validated by experimental results on SARS-CoV-2, reveals that Omicron may be over 10 times more contagious than the original virus or about 2.8 times as infectious as the Delta variant. On the basis of 185 three-dimensional (3D) structures of antibody-RBD complexes, we unveil that Omicron may have an 88% likelihood to escape current vaccines. The U.S. Food and Drug Administration (FDA)-approved monoclonal antibodies (mAbs) from Eli Lilly may be seriously compromised. Omicron may also diminish the efficacy of mAbs from AstraZeneca, Regeneron mAb cocktail, Celltrion, and Rockefeller University. However, its impacts on GlaxoSmithKline's sotrovimab appear to be mild. Our work calls for new strategies to develop the next generation mutation-proof SARS-CoV-2 vaccines and antibodies.